obinutuzumab,venetoclax,ibrutinib
roche,abbvie
['obinu', 'lymphoma', 'lymsm', 'cll', 'caveat', 'venetoclax', 'ibru']
finally, the #asco23 lymphoma session! ph 3 alliance cll trial of ivo vs io (ibrutinib+venetoclax+obinutuzumab; with response-adapted fixed duration vs ibr+obin continuous) headline: pfs &amp; os curves both superimposable slight caveat: more covid deaths in the ivo arm #lymsm 
haematology registrar | @harvardmed fellow @PORTAL_research | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer | SoMe Ed @BrJHaem